Successful Salvage Therapy With Quizartinib Plus Chemotherapy Followed by Quizartinib Monotherapy for Transplant Bridging and Post-Transplant Maintenance in a Child With Induction-Refractory FLT3-ITD-Positive AML.

IF 2.4 3区医学 Q2 HEMATOLOGY

Pediatric Blood & Cancer Pub Date : 2026-10-15 DOI:10.1002/1545-5017.70768

Keiji Tasaka, Koji Kawaguchi, Taemi Ogura, Hiroyuki Kuroda, Ryo Akazawa, Takayuki Takachi, Shota Kato, Masahiro Sekiguchi, Motohiro Kato, Kenichiro Watanabe

引用次数: 0

查看原文本刊更多论文

在一名患有诱导难治性flt3 - itd阳性AML的儿童中，Quizartinib联合化疗后再用Quizartinib单药治疗移植桥接和移植后维持治疗成功。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pediatric Blood & Cancer 医学-小儿科

CiteScore

4.90

自引率

9.40%

发文量

546

审稿时长

1.5 months

期刊介绍： Pediatric Blood & Cancer publishes the highest quality manuscripts describing basic and clinical investigations of blood disorders and malignant diseases of childhood including diagnosis, treatment, epidemiology, etiology, biology, and molecular and clinical genetics of these diseases as they affect children, adolescents, and young adults. Pediatric Blood & Cancer will also include studies on such treatment options as hematopoietic stem cell transplantation, immunology, and gene therapy.